



## **Design Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference**

June 7, 2021

CARLSBAD, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today reported that João Siffert, M.D., president and chief executive officer, will participate in a fireside chat during the Goldman Sachs 42<sup>nd</sup> Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 1:20 p.m. ET.

The live webcast will be available in the investor section of the company's website at [www.designtx.com](http://www.designtx.com). The webcast will be archived for 60 days following the presentation.

### **About Design Therapeutics**

Design Therapeutics is a biotechnology company developing a new class of therapies based on a platform of gene targeted chimera (GeneTAC™) small molecules. Our GeneTAC molecules are designed to either turn on or turn off a specific disease-causing gene to address the underlying cause of disease. The company's lead program is focused on the treatment of Friedreich ataxia, followed by a program in myotonic dystrophy type-1 and discovery efforts for multiple other serious degenerative disorders caused by nucleotide repeat expansions. For more information, please visit [designtx.com](http://designtx.com).

### **Contact:**

Alicia Davis  
THRUST Strategic Communications  
(910) 620-3302  
[alicia@thrustsc.com](mailto:alicia@thrustsc.com)